DLK1 and malignant colon neoplasm: We are currently focused on unraveling immune-mediated mechanisms involved in vascular changes induced by αDC1-DLK1 vaccination, particularly under orthotopic settings of colon cancer progression since s.c. tumor modeling may overestimate anti-vascular effects (due to increased angiogenesis) or not accurately reflect the CRC TME of patients (38, 64).